Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics Inc (TARA) is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access comprehensive coverage of TARA's investigational cell therapy TARA-002 for lymphatic malformations and IV Choline Chloride research. Our news collection features press releases, peer-reviewed data publications, and strategic partnership announcements.
Key updates include progress reports on:
• Clinical trial phases
• FDA designations
• Scientific conference presentations
• Intellectual property developments
Bookmark this page for centralized access to Protara's latest advancements in immunopotentiator therapies and metabolic replacement solutions. Monitor critical updates affecting the company's position in the oncology and rare disease treatment landscapes.
Protara Therapeutics (TARA) announced inducement grants of stock options and restricted stock units (RSUs) to six new employees. The company's new VP and Chief People Officer, Shane Williams, received 41,000 stock options at $4.32 per share and 20,500 RSUs on April 25, 2025. Additionally, five other new employees were granted a total of 59,100 stock options at $3.46 per share and 29,550 RSUs.
The stock options vest over four years (25% after one year, then 1/36th monthly), while RSUs vest over three years (33 1/3% annually). All grants were approved under the company's 2020 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
- 100% complete response rate at any time
- 100% at 6 months
- 80% at 9 months
- 67% at 12 months
In the BCG-Naïve cohort (21 patients):
- 76% complete response rate at any time
- 63% at 6 months
- 63% at 9 months
- 43% at 12 months
The treatment demonstrated a favorable safety profile with no Grade 3 or greater treatment-related adverse events. The company expects to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by end of 2025.
Protara Therapeutics (Nasdaq: TARA) has announced a conference call and webcast scheduled for April 28, 2025, at 8:30 a.m. ET to discuss interim data from their Phase 2 ADVANCED-2 trial. The presentation will focus on updated safety and efficacy data of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), specifically including data from patients who have reached the 12-month evaluation timepoint.
The data will also be presented during an interactive poster session at the American Urological Association 2025 Annual Meeting on April 26, 2025, at 7:00 a.m. PT. Interested participants can register for the conference call to receive dial-in information, and a live webcast will be available on the company's website.
Protara Therapeutics (Nasdaq: TARA) has appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer. Dr. Nicacio brings nearly 20 years of experience in oncology, drug development, regulatory and commercial sectors.
Prior to joining Protara, Dr. Nicacio served as Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics. He previously held the position of Vice President, Clinical Development at Seagen, where he managed development programs across multiple cancer types. His experience includes roles at AstraZeneca, Flatiron Health, Sanofi, and YM Biosciences.
The company is preparing to present interim data from the ADVANCED-2 clinical trial of TARA-002 in patients with non-muscle invasive bladder cancer later this month. Dr. Nicacio will contribute to Protara's mission of developing transformative therapies for cancer and rare diseases.
Protara Therapeutics (Nasdaq: TARA) announced upcoming presentations of interim analysis from their Phase 2 ADVANCED-2 trial of TARA-002 at the American Urological Association Annual Meeting in Las Vegas (April 26-29, 2025). The trial focuses on treating non-muscle invasive bladder cancer (NMIBC) patients.
The ADVANCED-2 trial (NCT05951179) is an open-label study evaluating intravesical TARA-002 in two patient groups: BCG-unresponsive (n≈100) and BCG-Naïve (n=30) with carcinoma in situ (CIS). The BCG-Unresponsive cohort is designed to be registrational in alignment with FDA's 2024 guidance.
Updated safety and efficacy data, including 12-month evaluation timepoint results, will be presented during an interactive poster session. The event will feature two presentations and a panel discussion with leading urologists and researchers.
Protara Therapeutics (Nasdaq: TARA) has announced an encore presentation of their THRIVE-1 study results at the ASPEN 2025 Nutrition Science & Practice Conference. The study revealed that 78% of patients dependent on parenteral support (PS) were choline deficient, with 63% of these patients showing liver dysfunction.
The company is developing intravenous (IV) Choline Chloride as a treatment for patients who cannot receive choline through oral or enteral nutrition. The treatment has received Fast Track designation from the FDA. Protara plans to initiate THRIVE-3, a registrational Phase 2b/3 trial, in the first half of 2025, which will include an 8-week dose confirmation phase with 24 patients, followed by a 24-week randomized, placebo-controlled phase with 100 patients.
Protara Therapeutics (NASDAQ: TARA) reported Q4 and full year 2024 results, highlighting significant pipeline progress. The company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in NMIBC patients, showing a 72% complete response rate at six months and a favorable safety profile.
Financial highlights include $170.3 million in cash and equivalents as of December 31, 2024, including proceeds from a $100 million public offering, expected to fund operations into 2027. Q4 net loss was $12.8 million ($0.48 per share), with full-year 2024 net loss at $44.6 million ($2.17 per share).
Key upcoming milestones include: initial 12-month data from ADVANCED-2 trial by mid-2025, first patient dosing in THRIVE-3 registrational trial in 1H 2025, and an interim update from STARBORN-1 trial in pediatric LMs by end of 1H 2025.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 9:50 am ET in Boston.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time after the event.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 12:40 pm ET.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time following the event.
Protara Therapeutics highlights recent updates and anticipated milestones for 2025. The company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in NMIBC patients, showing a 72% complete response (CR) rate at six months and a favorable safety profile. Data from 12-month evaluable patients is expected mid-2025, with futility analysis results by the end of 2025.
Protara completed a $100 million public offering, extending its financial runway into 2027. The THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support is set to begin in the first half of 2025. Initial results from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients are expected by the end of the first half of 2025.
The company remains focused on developing therapies for cancer and rare diseases, with ongoing efforts in combination therapies and regulatory alignments for future trials.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
